CG Oncology Files 8-K
Ticker: CGON · Form: 8-K · Filed: Dec 5, 2024 · CIK: 1991792
| Field | Detail |
|---|---|
| Company | Cg Oncology, Inc. (CGON) |
| Form Type | 8-K |
| Filed Date | Dec 5, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, financial-statements
TL;DR
CG Oncology filed an 8-K on Dec 5th, likely with important updates.
AI Summary
CG Oncology, Inc. filed an 8-K on December 5, 2024, to report on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text, but it confirms the company's reporting status.
Why It Matters
This filing indicates CG Oncology is making a regulatory disclosure, which could relate to significant company events or financial updates.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate negative or positive indicators in the provided text.
Key Players & Entities
- CG Oncology, Inc. (company) — Registrant
- December 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-41925 (identifier) — SEC File Number
- 37-1611499 (identifier) — IRS Employer Identification No.
- Irvine, California (location) — Principal Executive Offices
- (949) 409-3700 (phone_number) — Registrant's Telephone Number
FAQ
What specific events are being reported in this 8-K filing by CG Oncology, Inc.?
The provided text indicates the 8-K is for 'Other Events' and 'Financial Statements and Exhibits', but does not detail the specific events.
When was this 8-K filing submitted by CG Oncology, Inc.?
The filing was submitted on December 5, 2024.
What is CG Oncology, Inc.'s principal executive office address?
The principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, California, 92618.
What is CG Oncology, Inc.'s SEC file number?
CG Oncology, Inc.'s SEC file number is 001-41925.
What is the SIC code for CG Oncology, Inc.?
The Standard Industrial Classification (SIC) code for CG Oncology, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,547 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2024-12-05 07:52:59
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share CGON The Nasdaq Global Se
Filing Documents
- d809707d8k.htm (8-K) — 35KB
- d809707dex991.htm (EX-99.1) — 15KB
- g809707g1204213130383.jpg (GRAPHIC) — 7KB
- 0001193125-24-271116.txt ( ) — 192KB
- cgon-20241205.xsd (EX-101.SCH) — 3KB
- cgon-20241205_lab.xml (EX-101.LAB) — 18KB
- cgon-20241205_pre.xml (EX-101.PRE) — 11KB
- d809707d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company's current beliefs and expectations and include, but are not limited to: the potential therapeutic benefits of cretostimogene for high-risk and intermediate-risk NMIBC patients and its potential to have best-in-class durable response and meaningfully improve patient outcomes, and the importance of the data as they relate to addressing bladder cancer. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company's business, including, without limitation: additional patient data related to cretostimogene that continues to become available may be inconsistent with the data produced as of the data cutoff, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; potential delays in the commencement, enrollment and completion of clinical trials; competitive developments with respect to current and other investigational NMIBC treatments may adversely affect the commercial opportunity of cretostimogene; and other risks described in the Company's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in the Company's annual report on Form 10-K and any subsequent filings with the SEC (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits Exhibit No. Description 99.1 Press release, dated December 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CG Oncology, Inc. Date: December 5, 2024 By: /s/ Josh Patterson Name: Josh Patterson Title: General Counsel and Chief Compliance Officer